

GLOBAL ACADEMY *of* **WOMEN'S CANCER**

**EUROPEAN
HYBRID MEETING**

Simply the Best Education
you can get

14/15
APRIL
2023
MADRID
SPAIN

FINAL PROGRAM

CONTENT

Welcome Message	•	1
Programme at a Glance	•	2–3
Programme Friday, April 14 th	•	4–7
Programme Saturday, April 15 th	•	8–10
Executive Board	•	11
Invited Faculty	•	12–13
Satellite Symposia Overview	•	14–15
Floor Plan	•	16
General Information	•	17–18
Sponsors	•	19

Dear Colleagues and Friends,

The 1st meeting of the Global Academy of Women's Cancer was held in Vienna on October 8–9, 2021.

We welcomed nearly 700 participants to the kick-off in person and virtually. The overall feedback from attendees was overwhelmingly positive, reinforcing our belief that the format was spot on in combining all women's cancers into one educational meeting. Therefore, we held the second Global Academy event on July 8–9, 2022 in Munich, Germany.

Once again, the hybrid format with 250 participants live in Munich and another 460 participants online, were a great success for us.

In 2023, the Global Academy of Women's Cancer will meet for its 3rd International Meeting on April 14/15, 2023 in Madrid, Spain.

We invite you to attend keynote lectures, debates, Speakers Corner, Meet the Professor sessions, multidisciplinary panel discussions, case discussions, and sessions on the hot topics. During the 1.5-day meeting in Madrid, the latest results and treatment strategies will be summarized, discussed and presented by international experts.

The interactive congress offers a comprehensive overview of all new developments in breast and gynecological cancers, which account for 50% of all cancers in women, as well as direct exchange with the world's leading experts in these fields. The aim is to present the latest scientific findings in practical recommendations for everyday clinical practice.

We would like to invite you to actively participate in the event!

Join us and exchange ideas with your colleagues and experts from all over the world, broaden your knowledge and take away ideas and recommendations for your daily work.

We look forward to welcoming you in Madrid!

Andreas du Bois, MD
Scientific Chair

Jonathan Ledermann, MD
Scientific Chair

Sherko Kümmel, MD
Scientific Chair

Peter Schmid, MD
Scientific Chair

Luis Chiva, MD
Local Scientific Chair

Javier Cortes, MD
Local Scientific Chair


Antonio González-Martin, MD
Local Scientific Chair

PROGRAMME AT A GLANCE

Friday, April 14th

Madrid 1/2

Madrid 4



Saturday, April 15th

Madrid 1/2

Madrid 4

8:30	BREAST CANCER SESSION III	GYNAE-ONCOLOGY SESSION III
9:00		
10:00	BREAK	
	SATELLITE SYMPOSIUM II	
11:00		
	SCIENTIFIC SYMPOSIUM II	
12:00		
	BREAK	
13:00	BREAST CANCER SESSION IV	GYNAE-ONCOLOGY SESSION IV
14:00		
15:00	BREAK	
	JOINT LECTURE III	
16:00		
	CLOSING REMARKS AND FAREWELL	
17:00		
18:00		
19:00		

Friday, April 14th

10:00–11:00

MEET THE EXPERTS SESSIONS

- 10:00–11:00 [Room Gran Via / Floor 3](#)
Managing the side-effects of new drugs including immuno-oncology
Peter Schmid, London, United Kingdom
- 10:00–11:00 [Room Chamberi / Floor 3](#)
Current topics and standards in breast cancer surgery after neoadjuvant therapy
Jens-Uwe Blohmer, Berlin, Germany
- 10:00–10:30 [Room Colon / Floor 3](#)
Selection criteria for surgery in recurrent Ovarian Cancer
Andreas du Bois, Essen, Germany
- 10:30–11:00 [Room Colon / Floor 3](#)
How to treat rare epithelial Ovarian Cancer
Jonathan Ledermann, London, United Kingdom

11:00

WELCOME

11:15–12:15 | Madrid 1/2

JOINT LECTURE I

MY PERSONAL HIGHLIGHTS OF 2022

CHAIRS: ANTONIO GONZALEZ MARTIN, MADRID, SPAIN
JAVIER CORTES, BARCELONA, SPAIN

- 11:15–11:35 ... in Breast Cancer (clinical)
Hope S. Rugo, San Francisco, USA
- 11:35–11:55 ... in Breast Cancer (basic and translational)
 Fabrice André, Villejuif, France
- 11:55–12:15 ... in Gynaecological Oncology
Nicole Concin, Innsbruck/Essen, Austria/Germany

12:15–13:15 | Madrid 1/2

SCIENTIFIC SYMPOSIUM I CDK4/6*This Scientific Symposium is kindly supported by an unconditional educational grant from Eli Lilly.***CDK4/6i DIFFER IN THEIR EFFICACY REGARDING SURVIVAL – YES OR NO**CHAIRS: SHERKO KÜMMEL, ESSEN, GERMANY
HOPE S. RUGO, SAN FRANCISCO, USA12:15–12:35 **Pro: Yes – we have different CDK4/6 Inhibitors for survival**
Nadia Harbeck, Munich, Germany12:35–12:55 **Contra: No – we don't have different CDK4/6 Inhibitors for survival**
Antonio Llombart Cussac, València, Spain12:55–13:15 **Panel Discussion:**
Nadia Harbeck, Munich, Germany
Miguel Martin, Madrid, Spain
Giuseppe Curigliano, Milan, Italy
Antonio Llombart Cussac, Valencia, Spain
Hope S. Rugo, San Francisco, USA

13:15–14:15

BREAK

14:15–15:15 | Madrid 1/2

JOINT LECTURE II**HEREDITARY BREAST AND GYNAE-CANCER/GENETICS**CHAIRS: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM
SHANI PALUCH-SHIMON, TEL AVIV, ISRAEL14:15–14:30 **Hereditary Breast Cancer and BRCA: ESMO guidelines on risk assessment, genetic testing and clinical consequences**
Shani Paluch-Shimon, Tel Aviv, Israel14:30–14:35 **Discussion**14:35–14:50 **Keynote lecture: Hereditary cancer syndroms in Gynecological Oncology**
Nicoletta Colombo, Milan, Italy14:50–14:55 **Discussion**14:55–15:10 **Prophylactic surgery in hereditary cancer syndromes.**
Isabel Rubio, Madrid, Spain15:10–15:15 **Discussion**

Friday, April 14th

15:15–15:45

BREAK

15:45–17:15 | Madrid 1/2

BREAST CANCER SESSION I

ADJUVANT THERAPY IN HR-POSITIVE BREAST CANCER

CHAIRS: ANTONIO LLOMBART CUSSAC, VALENCIA, SPAIN
MIGUEL MARTIN, MADRID, SPAIN

KEYNOTE LECTURES

- 15:45–16:05 Optimal endocrine therapy
Michael Gnant, Vienna, Austria
- 16:05–16:25 Who benefits from adjuvant CDK 4/6 inhibitors?
Miguel Martin, Madrid, Spain
- 16:25–16:45 Who benefits from adjuvant chemotherapy in ER+ Breast Cancer?
Nadia Harbeck, Munich, Germany

CASE DISCUSSION

- 16:45–17:00 Premenopausal ER+ breast cancer – ovarian suppression, fertility and pregnancy
Alessandra Gennari, Genova, Italy
- 17:00–17:15 Discussion

15:45–17:15 | Madrid 4

GYNÆ-ONCOLOGY SESSION I

CERVICAL CANCER

CHAIRS: MANSOOR RAZA MIRZA, COPENHAGEN, DENMARK
NICOLETTA COLOMBO, MILAN, ITALY

DEBATE Cervical Cancer FIGO IB – which surgical approach/technique for whom

- 15:45–16:05 Open radical hysterectomy
David Cibula, Prague, Czech Republic
- 16:05–16:25 Laparoscopic hysterectomy
Luis Chiva, Madrid, Spain
- 16:25–16:45 Simple hysterectomy
Marie Plante, Quebec, Canada
- 16:45–17:00 Discussion

CASE DISCUSSION

- 17:00–17:15 Recurrent cervical cancer after radio chemotherapy
Nicoletta Colombo, Milan, Italy

17:15–17:45

BREAK

17:45–18:45 | Madrid 1/2

SATELLITE SYMPOSIUM I

see separate satellite symposium program on page 14

18:45–19:45 | Madrid 1/2

BREAST CANCER SESSION II

EBC – TNBC

CHAIRS: PETER SCHMID, LONDON,
UNITED KINGDOM
SHAHEENAH DAWOOD, DUBAI,
UNITED ARAB EMIRATES

18:45–19:05 Update on treatment of early TNBC
**Peter Schmid, London,
United Kingdom**

DEBATE

19:05–19:45 Should we escalate or de-escalate
depending on response to neoadju-
vant chemo plus CIT in eTNBC? Role
of adjuvant CIT and/or treatment/
combination with capecitabine/
PARPi

19:05–19:15 Pro
Carlos Barrios, Porto Alegre, Brazil

19:15–19:25 Contra
Giuseppe Curigliano, Milan, Italy

19:25–19:45 Panel Discussion
Carlos Barrios, Porto Alegre, Brazil
**Shaheenah Dawood, Dubai,
United Arab Emirates**
**Peter Schmid, London,
United Kingdom**
Giuseppe Curigliano, Milan, Italy
**Oleg Gluz, Moenchengladbach,
Germany**

18:45–19:45 | Madrid 4

GYNAE-ONCOLOGY SESSION II

ENDOMETRIAL CANCER

CHAIRS: NICOLETTA COLOMBO, MILAN, ITALY
MARIE PLANTE, QUEBEC, CANADA

KEYNOTE LECTURES

18:45–19:00 Precision adjuvant therapy in
Endometrial Cancer
David Tan, Singapore

19:00–19:15 Actual status of immuno-oncology
in Endometrial Cancer
**Mansoor Raza Mirza,
Copenhagen, Denmark**

19:15–19:30 Targeted therapy beyond immuno-
oncology in Endometrial Cancer
**Jose Alejandro Perez-Fidalgo,
Valencia, Spain**

19:30–19:45 Discussion

Saturday, April 15th


08:30–10:00 | Madrid 1/2

BREAST CANCER SESSION III

EBC HER2+

CHAIRS: JAVIER CORTES, BARCELONA, SPAIN
HOPE S. RUGO, SAN FRANCISCO, USA

KEYNOTE LECTURE

08:30–08:50 Update on treatment of HER2+ EBC
 Sara Tolaney, Boston, USA

CASE DISCUSSION

08:50–09:40 Can we escalate or de-escalate depending on response to neoadjuvant HER2-targeted therapy? Role of shorter vs longer chemotherapy + HER2-blockade and/or adjuvant HER2-targeted therapy

08:50–09:05 Pro:
Sherko Kümmel, Essen, Germany

09:05–09:20 Contra:
Carlos Barrios, Porto Alegre, Brazil

09:20–09:40 Panel Discussion
Nadia Harbeck, Munich, Germany
Carlos Barrios, Porto Alegre, Brazil
Sherko Kümmel, Essen, Germany
Giuseppe Curigliano, Milan, Italy

KEYNOTE LECTURE

This Scientific Lecture is kindly supported by an unconditional educational grant from Daiichi Sankyo.

09:40–10:00 ADC's in Her2-overexpression
Javier Cortes, Barcelona, Spain

08:30–10:00 | Madrid 4

GYNAE-ONCOLOGY SESSION III

SURGICAL QUESTIONS IN GYNECOLOGICAL ONCOLOGY

CHAIRS: LUIS CHIVA, MADRID, SPAIN
NICOLE CONCIN, INNSBRUCK/ESSEN, AUSTRIA/GERMANY

DEBATE

Complete clinical/radiological remission after 4 courses of neoadjuvant treatment of ovarian cancer. What to do?

08:30–08:40 Open IDS
Philippe Morice, Villejuif, France

08:40–08:50 Laparoscopic IDS
Christian Marth, Innsbruck, Austria

08:50–09:00 No surgery necessary
Ignacio Romero Noguera, Valencia, Spain

09:00–09:10 Discussion

CASE DISCUSSION

09:10–09:30 Case 1: Management of FIGO 4
Andreas du Bois, Essen, Germany

09:30–09:35 Discussion

09:35–09:55 Case 2: Minor response after NACT: IDS or not?
Christina Fotopoulou, London, United Kingdom

09:55–10:00 Discussion

10:00–10:15

BREAK

10:15–11:15 | Madrid 1/2

SATELLITE SYMPOSIUM II

see separate satellite symposium program on page 15

Saturday, April 15th

11:15–12:00 | Madrid 1/2

SCIENTIFIC SYMPOSIUM II SERD'S

CHAIR: JAVIER CORTES, BARCELONA, SPAIN

11:15–11:30 Do we need SERD's

□ **Aditya Bardia, Boston, USA**

11:30–11:45 2ndline (hormone) treatment options after CDK4/6

Hope S. Rugo, San Francisco, USA

11:45–12:00 Endocrine Resistance at HR+ mBC – what we know?

□ **Fabrice Andre, Villejuif, France**

12:00–13:00

BREAK

13:00–14:45 | Madrid 1/2

BREAST CANCER SESSION IV

METASTATIC BREAST CANCER

CHAIRS: NADIA HARBECK, MUNICH, GERMANY

CASE DISCUSSION

13:00–13:10 Optimal treatment sequences after adjuvant CDK4/6 inhibitors

Oleg Gluz, Moenchengladbach, Germany

13:10–13:15 Discussion

LECTURES

13:15–13:25 Update on management of mTNBC

□ **Rebecca Dent, Singapore**

13:25–13:35 Update on management of ER+ MBC

Giuseppe Curigliano, Milan, Italy

13:35–13:45 Update on management of HER2+ MBC

Javier Cortes, Barcelona, Spain

13:45–14:05 Discussion

DEBATE

14:05–14:45 CNS disease – Should we prioritise systemic therapy or radiotherapy?

14:05–14:20 Pro: Systemic therapy

Carlos Barrios, Porto Alegre, Brazil

14:20–14:35 Pro: Radiotherapy

Montserrat Pazos, Munich, Germany

14:35–14:45 Discussion

13:00–14:45 | Madrid 4

GYNAE-ONCOLOGY SESSION IV

SYSTEMIC TREATMENT OF OVARIAN CANCER

CHAIRS: ANDREAS DU BOIS, ESSEN, GERMANY

DAVID TAN, SINGAPORE

DEBATE

13:00–13:45 Do we need HRD testing?

13:00–13:15 Pro:

Jonathan Ledermann, London, United Kingdom

13:15–13:30 Contra:

Antonio Gonzalez-Martin, Madrid, Spain

13:30–13:45 Discussion

KEYNOTE LECTURES

13:45–14:00 Treatment of recurrent ovarian cancer after PARPi

Amit Oza, Toronto, Canada**CASE DISCUSSION**

14:00–14:20 Case 4: ROC: During maintenance after Paola-like maintenance regimen with BEV+ PARPi and platinum free interval of 8 months

David Tan, Singapore

14:20–14:25 Discussion

Saturday, April 15th

14:45–15:15

BREAK

15:15–16:40 | Madrid 1/2

JOINT LECTURE III

PRECISION MEDICINE AND NEW DEVELOPMENTS

CHAIRS: AMIT OZA, TORONTO, CANADA

SHERKO KÜMMEL, ESSEN, GERMANY

15:15–15:35 Where we are in ADC's in Breast Cancer- future developments
Hope S. Rugo, San Francisco, USA

15:35–15:40 Discussion

15:40–15:55 New drugs, new toxicities, new challenges
Antonio Gonzalez-Martin, Madrid, Spain

15:55–16:00 Discussion

16:00–16:15 Quality of Life during PARPi treatment
Maria Pilar Barretina Ginesta, Girona, Spain

16:15–16:20 Discussion

16:20–16:35 Breast Cancer: Integrating molecular pathology and personalised medicine into routine daily patient treatment
 Fabrice André, Villejuif, France

16:35–16:40 Discussion

16:45

CLOSING REMARKS AND FAREWELL

Initiators of the Global Academy of Women's Cancer

Andreas du Bois, MD
Essen, Germany

Jonathan Ledermann, MD
London, United Kingdom

Sherko Kümmel, MD
Essen, Germany

Peter Schmid, MD
London, United Kingdom

Scientific Board Gynaecological Oncology

Nicoletta Colombo, MD
Milan, Italy

Amit Oza, MD
Toronto, Canada

**Antonio
González-Martin, MD**
Madrid, Spain

David Tan, MD
Singapore

Scientific Board Breast Cancer

Carlos Barrios, MD
Rio de Janeiro, Brazil

Rebecca Dent, MD
Singapore

Javier Cortes, MD
Barcelona, Spain

Nadia Harbeck, MD
Munich, Germany

INVITED FACULTY

Fabrice André

Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France
fabrice.andre@gustaveroussy.fr

Aditya Bardia

Mass General Cancer Center:
Hematology Oncology
55 Fruit St.
Boston, MA 02114
bardia.aditya@mgh.harvard.edu

Maria Pilar Barretina Ginesta

ICO Girona – Hospital Universitario
Doctor Josep Trueta
Avenida França s/n
17007 Girona, Spain
mpbarretina@iconcologia.net

Carlos Barrios

Oncoclínicas Group
Oncology Research Center, São Lucas
Hospital, PUCRS
Latin American Cooperative Oncology
Group (LACOG)
Coroados 837
Porto Alegre RS 9190580 Brazil
barrios@tummi.org

Jens-Uwe Blohmer

Campus Charité Mitte
Anschrift: Charitéplatz 1
10117 Berlin, Germany
jens.blohmer@charite.de

Andreas du Bois

Evang.Kliniken Essen-Mitte
Huyssens-Stiftung Essen-Huttrop
Klinik für Gynäkologie und
Gynäkologische Onkologie
Henricistr. 92
45136 Essen, Germany

Luis Chiva

Clinica Universidad de Navarra
Marquesado de Santa Marta Street 1
28027, Madrid, Spain
lchiva@unav.es

David Cibula

Charles University and General
University Hospital
First Faculty of Medicine
LF UK Praha
Kateřinská 32
121 08 Prague 2

Nicoletta Colombo

Divisione di Ginecologia Oncologia
Medica
IRCCS Istituto Europeo di Oncologia
Via Ripamonti 435
20144 Milan, Italy
nicoletta.colombo@ieo.it

Nicole Concini

Evang. Kliniken Essen-Mitte
Essen, Germany
University of Innsbruck
Innsbruck, Austria
n.concini@kem-med.com
nicole.concini@i-med.ac.at

Javier Cortes

Vall d'Hebron Institute of Oncology
Centro Cellex, Carrer de Natzaret,
115–117
08035 Barcelona, Spain
jacortes@vhio.net

Giuseppe Curigliano

University of Milan
Via Ripamonti, 435 – IEO – Istituto
Europeo di Oncologia
20141 Milan, Italy
giuseppe.curigliano@unimi.it

Shaheenah Dawood

Mediclinic Middle East
Dubai Healthcare City, Bldg 37
Dubai, United Arab Emirates

Rebecca Dent

National Cancer Center Singapore
11 Hospital Cres
Singapore 169610
rebecca.dent@singhealth.com

Christina Fotopoulou

Imperial College London
Hammersmith Hospital
Du Cane Road, W12 7BH
London, UK
christina.fotopoulou@nhs.net

Alessandra Gennari

Maggiore Hospital Novara
Corso Mazzini n. 18
28100 Novara, Italy
alessandra.gennari@med.uniupo.it

Michael Gnant

Medizinische Universität Wien
Brustgesundheitszentrum
Waehringer Guertel 18–20
1090 Vienna, Austria
michael.gnant@meduniwien.ac.at

Oleg Gluz

Brustzentrum Niederrhein
Ludwig-Weber-Straße 15
41061 Mönchengladbach, Germany
oleg.gluz@wsg-online.com

Antonio González-Martin

Servicio de Oncologia Medica
Clinica Universidad de Navarra
Avenida P o XII, 36
31008 Madrid, Spain
aqonzalezma@unav.es

Nadia Harbeck

Frauenkliniken Großhadern und
Maistrasse-Innenstadt
Brustzentrum der Universität
München
Marchioninstr. 15
81377 Munich, Germany
nadia.harbeck@med.uni-muenchen.de

Sherko Kümmel

Evangel. Kliniken Essen-Mitte
Huyssens-Stiftung Essen-Huttrop
Klinik für Senologie/Brustzentrum
Henricistr. 92
45136 Essen, Germany
s.kuemmel@kliniken-essen-mitte.de

Jonathan Ledermann

Clinical Director
UCL Cancer Institute
Department of Oncology
72 Huntley Street,
London WC1E 6DD
United Kingdom
j.ledermann@ucl.ac.uk

Antonio Llombart Cussac

Arnao de Vilanova Hospital
of Valencia
Carrer de Sant Clement, 12
46015 València, Spain

Christian Marth

Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie
und Geburtshilfe
Anichstr. 35
6020 Innsbruck, Austria
christian.marth@i-med.ac.at

Miguel Martin

Hospital General Universitario
Gregorio Marañón
C. del Dr. Esquerdo, 46
28007 Madrid, Spain

Mansoor Raza Mirza

Nordic Society of Gynaecological
Oncology
Dept. of Oncology
9431 Rigshospitalet
Copenhagen University Hospital
Blegdamsvej 9
2100 Copenhagen, Denmark
mansoor.raza.mirza@regionh.dk

Philippe Morice

Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France
philippe.morice@gustaveroussy.fr

Ignacio Romero Noguera

Medical Oncology Department, IVO
C/Beltrán Bagueña, 8
46009 Valencia, Spain

Amit Oza

Ontario Institute for Cancer Research
MaRS Centre
661 University Avenue, Suite 510
Toronto, Ontario Canada, M5G 0A3
amit.oza@uhn.ca

Shani Paluch-Shimon

Hadassah University Hospital
Kiryat Hadassah
Jerusalem 91120, Israel

Montserrat Pazos

LMU Hospital
Clinic and Polyclinic for
Radiotherapy and Radiooncology
Campus Innenstadt
Ziemssenstr. 1
80336 Munich, Germany
montserrat.pazos@
med.uni-muenchen.de

Jose Alejandro Perez-Fidalgo

Servicio de Oncología
Hospital Clínico Universitario
de Valencia
Avenida Blasco Ibáñez, 17
46010 Valencia, Spain

Marie Plante

Department of Obstetrics,
Gynecology, and Reproduction
Faculty of Medicine, Université Lava
L'Hôtel-Dieu de Québec
11, côte du Palais
Québec, G1R 2J6, Canada

Isabel Rubio

Cancer Center Universidad
de Navarra
C. del Marquésado de Sta. Marta, 1
28027 Madrid, Spain

Hope S. Rugo

University of California San Francisco
UCSF Helen Diller Family
Comprehensive Cancer Center
1450 3rd St.
San Francisco, CA 94158

Peter Schmid

Barts Cancer Institute
Charterhouse Square Campus
Charterhouse Square
London EC1M 5PZ, United Kingdom
p.schmid@qmul.ac.uk

David Tan

Cancer Science Institute (CSI)
14 Medical Dr,
#12-01 Centre for Translational
Medicine
Singapore 117599
david_sp_tan@nuhs.edu.sg

Sara M. Tolaney

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215, USA
Sara_Tolaney@dfci.harvard.edu



Friday, April 14th

17:45–18:45

SATELLITE SYMPOSIUM I

GSK

CHAIR: ANTONIO GONZÁLEZ-MARTÍN, MADRID, SPAIN

Advancing the Treatment Landscape of OC and EC Through Early, Biomarker-informed Targeted Therapies

Latest Advances in Diagnosis and Treatment of Gynecologic Cancer

Antonio González-Martín, Madrid, Spain

PARP Inhibitors and the Evolution of Personalized Medicine in Advanced Ovarian Cancer

Maria-Pilar Barretina-Ginesta, Girona, Spain

Panel Discussion

All

PD-(L)1 Inhibitors in Advanced or Recurrent Endometrial Cancer – Recent Advances and Future Direction

Nicole Concin, Innsbruck, Austria / Essen, Germany

Panel Discussion and Q & A

All

Saturday, April 15th

10:15–11:15 **SATELLITE SYMPOSIUM II**

Astra Zeneca

CHAIR: ANTONIO GONZÁLEZ MARTIN, MADRID, SPAIN

**New perspectives on women's cancer therapy:
exploring untrodden pathways**


- 10:15–10:25 Welcome & Introduction
Current landscape and evolution
trends in personalized medicine
Antonio González Martin, Madrid, Spain
- 10:25–10:40 Targeting DNA repair and cell proliferation
beyond iPARPs
Marta Gil, Barcelona, Spain
- 10:40–10:45 Discussion
- 10:45–11:00 Overcoming endocrine resistance in BC:
New SERDs in the horizon
Antonio Llombart Cussac, València, Spain
- 11:00–11:05 Discussion
- 11:05–11:15 Conclusions and concluding remarks



FLOOR PLAN

Room Plan

4th Floor



CME Credits

The **Global Academy of Women's Cancer – European Hybrid Meeting, Madrid, Spain, 14/04/2023–15/04/2023** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **11 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of *AMA PRA Category 1 Credits™*.

Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

How to receive your CME Credits

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey, received by email.

Congress Date

April 14th – April 15th, 2023

Congress Organization

MEDCONCEPT 

Gesellschaft für medizinische Projekte mbH



Project Manager:

Mrs. Beatrice Schröder

E-Mail: beatrice.schroeder@medconcept.org

Friedenstr. 58

15366 Neuenhagen bei Berlin, Germany

Phone: +49 (0)3342 42689-13

Fax: +49 (0)3342 42689-40

E-Mail: info@medconcept.org

Internet: www.medconcept.org

Congress Website

<http://www.global-academy-of-womens-cancer.org>

GENERAL INFORMATION

Congress Venue

HOTEL RIU PLAZA ESPAÑA
BuildingC/ Gran Vía, 84
28013 Madrid
Spain

Exhibition

A commercial exhibition will be held at the congress venue, close to the main meeting room.

Exhibition Opening Hours

Friday, April 14th, 2023: 09:00–18:00

Saturday, April 15th, 2023: 09:00–17:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

Registration is on the 4th floor of the hotel's event area directly in front of the entrance to the meeting rooms.

Registration Desk Opening Hours

Thursday, April 13th, 2023 17:00–19:00 (early check-in)

Friday, April 14th, 2023 09:00–19:00

Saturday, April 15th, 2023 07:30–17:00

SPONSORS

Platinum




Gold




Silver



Bronze



PLATINUM: 120,000 EURO
GOLD: 90,000 EURO
SILVER: 50,000 EURO
BRONZE: 30,000 EURO



Advancing the Treatment Landscape of OC and EC Through Early, Biomarker-informed Targeted Therapies



Friday
14 April 2023
17:45-18:45 CET
Room Madrid 1/2
Madrid, Spain



CHAIR

Antonio González-Martín, MD

Universidad de Navarra
Madrid, Spain



María Pilar Barretina-Ginesta, MD

Catalan Institute of Oncology
Girona, Spain



Nicole Concin, MD

Innsbruck Medical University
Innsbruck, Austria

AGENDA

- **Latest Advances in Diagnosis and Treatment of Gynecologic Cancer**
Antonio González-Martín, MD (Chair)
- **PARP Inhibitors and the Evolution of Personalized Medicine in Advanced Ovarian Cancer**
María Pilar Barretina-Ginesta, MD
- **Panel Discussion**
All
- **PD-(L)1 Inhibitors in Advanced or Recurrent Endometrial Cancer – Recent Advances and Future Direction**
Nicole Concin, MD
- **Panel Discussion and Q&A**
All

Sponsored by

GSK

IN PATIENTS WITH HR+, HER2- BREAST CANCER
AT HIGH RISK OF RECURRENCE IN EBC OR IN THOSE WITH MBC^{1,4**}

Verzenios[®]
abemaciclib
twice a day

SHE NEEDS ALL THE
hope in the world
AND MORE

Verzenios is the first and only CDK4 & 6 inhibitor approved
in both EBC and MBC^{1,5-11}

Not all CDK4 & 6 inhibitors are the same^{1,5-9}

	Approved in EBC	Approved in MBC ^a	Continuous dosing schedule ^{12, b, c}	Continuous cell cycle arrest (in vitro) ¹³
Verzenios	✓	✓	✓	✓
Ribociclib		✓		
Palbociclib		✓		

*Verzenios is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of patients with certain types of HR+, HER2-locally advanced or metastatic breast cancer.¹

^bThe recommended starting dose of Verzenios is 150 mg twice a day for 2 years until disease recurrence in EBC, or until disease progression in MBC, or unacceptable toxicity in either setting.¹ Dosing interruption and/or dose reductions may be required based on individual safety and tolerability. Please refer to full Prescribing Information for additional guidance.

^cThe relationship between dosing and clinical outcomes has not been determined. Differences in dosing regimens cannot be used to establish differences in efficacy or safety.

Early Breast Cancer

Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with HR+, HER2-, node-positive EBC at high risk of recurrence.*

In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with an LHRH agonist.¹

Advanced or Metastatic Breast Cancer

Verzenios is indicated for the treatment of women with HR+, HER2- locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.¹ Kisqali is indicated for the treatment of women with HR+, HER2- locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.³ Ibrance is indicated for the treatment of HR+, HER2- locally advanced or metastatic breast cancer:

- in combination with an aromatase inhibitor;
- in combination with fulvestrant in women who have received prior endocrine therapy

In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.⁹ The information herein is not presented to compare the efficacy or safety profile of the discussed compounds. No implication of superiority or inferiority is intended or should be inferred, as the statements herein do not necessarily correlate with clinical outcomes.

There have been no head-to-head clinical studies among any of these products: Verzenios, Kisqali, and Ibrance. This information is derived from publications for the respective products, which are based on presently available data.

This information neither conveys, nor attempts to convey, the full benefit-risk profile of each product described. Treatment decisions are made based on a number of different factors related to the disease, patient, and potential therapy under consideration.

*High-risk EBC was defined as patients who had 4+ positive nodes or 1-3 positive nodes and tumors that were ≥5 cm, histological Grade 3, or both.¹

¹High-risk MBC was defined as having disease characteristics that could confer a worse prognosis, such as liver metastases, Pgr- status, and high tumor grade in primary tumor.^{2,4}

CDK=cyclin-dependent kinase; EBC=early breast cancer; HER2=Human Epidermal Growth Factor Receptor 2-negative; HR+=Hormone Receptor-positive; LHRH=luteinizing hormone-releasing hormone; MBC=metastatic breast cancer; Pgr=progesterone receptor-negative.

REFERENCES: 1. Verzenios (abemaciclib) Summary of Product Characteristics. Lilly, LLC. 2. Di Leo A, O'Shaughnessy J, Sledge GW Jr, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. *NPJ Breast Cancer*. 2018;4:41. doi:10.1038/s41523-018-0094-2 3. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35(25):2875-2884. 4. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. *JAMA Oncol*. 2020;6(1):116-124. 5. Mayer EL, Ducek AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2021;22(2):212-222. doi:10.1016/S1473-2045(20)30642-2 6. ClinicalTrials.gov. A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer (NATALEE). Accessed February 18, 2022. <https://clinicaltrials.gov/ct2/show/NCT03701334>. 7. Lobi S, Marmé F, Martin M, et al. Palbociclib for residual high-risk of relapse in HR-positive and HER2- early breast cancer—the Penelope-B trial. *J Clin Oncol*. 2021;39(14):1518-1530. 8. Kisqali Summary of Product Characteristics. Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuremberg, Germany. 9. Ibrance Summary of Product Characteristics. Pfizer Europe MA EIG Boulevard de la Plaine 17, 1050 Bruxelles, Belgium. 10. Verzenios (Abemaciclib) Prescribing Information. Lilly LLC 11. Patnak A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discov*. 2016;6(7):740-753. doi:10.1158/2159-8290.CD-16-0095 12. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent independent anti-tumor activities alone/in combination with gemcitabine. *Invest New Drugs*. 2014;32:825-837. 13. Torres-Guzman R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. *Oncotarget*. 2017;8:69493-69507. 14. Johnston SRD, Toi O'Shaughnessy J, et al; on behalf of monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2023;24(1)(suppl 1):77-90. doi:10.1016/S1473-2045(22)00694-5

VERZENIOS IS DOING
MORE WITH **NEW**
4-YEAR
DATA¹⁴

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento. The new indication for early breast cancer, authorized by the European regulators on April 1, 2022, is currently under review by the Spanish health authorities to determine pricing and reimbursement conditions. La nueva indicación de cáncer de mama en estadios iniciales, autorizada por las autoridades sanitarias europeas con fecha 1 de abril de 2022, está actualmente en trámite ante las autoridades sanitarias españolas para determinar las condiciones de financiación pública. PP-AL-ES-0788 ©Lilly, LLC 2023. All rights reserved. Verzenios® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. All other trademarks are the property of their respective owners.

Please see full local SmPC for
Verzenios here:



Lilly
TAKE HOPE
FURTHER

Together into the future

Plan with us your next
scientific event



MedConcept Gesellschaft
für medizinische Projekte mbH
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

MEDCONCEPT 
Experience since 1997

IMPORTANT INFORMATION

Certificate of Attendances

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

Congress WIFI

Username: GAWC23 x LILLY

Password: GAWC2023

